Skip to content
10-Q

Quarterly Report

Oragenics, Inc. OGEN

0001493152-26-021967

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 4.51M sh
Shares Diluted Q1 2026 · Mar 31, 2026 4.3M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 607.21K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.2M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.11M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $6.11M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $4.4M
Stockholders Equity Q1 2026 · Mar 31, 2026 $6.18M
Stockholders Equity Q1 2026 · Dec 31, 2025 $8.28M
Stockholders Equity Q1 2026 · Mar 31, 2025 $137.69K
Stockholders Equity Q1 2026 · Dec 31, 2024 −$211.89K
Total Liabilities Q1 2026 · Mar 31, 2026 $1.31M
Total Liabilities Q1 2026 · Dec 31, 2025 $1.79M
Current Assets Q1 2026 · Mar 31, 2026 $7.49M
Current Assets Q1 2026 · Dec 31, 2025 $10.07M
Total Assets Q1 2026 · Mar 31, 2026 $7.49M
Total Assets Q1 2026 · Dec 31, 2025 $10.07M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.51
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$3.65
Eps Basic Q1 2026 · Mar 31, 2026 −$0.51
Eps Basic restated Q1 2026 · Mar 31, 2025 −$3.65
Rd Expense Q1 2026 · Mar 31, 2026 $645.47K
Rd Expense Q1 2026 · Mar 31, 2025 $341.54K
Net Income Q1 2026 · Mar 31, 2026 −$2.2M
Net Income Q1 2026 · Mar 31, 2025 −$2.22M
Operating Income Q1 2026 · Mar 31, 2026 −$2.26M
Operating Income Q1 2026 · Mar 31, 2025 −$2.03M
Short Term Investments Q1 2026 · Dec 31, 2025 $4M